drugset / Trial / NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Timeline
- Start
- 2025-10-09
- Primary completion
- 2028-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adabelimumab | Unknown | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |
| Subject | SHR2554 | Small molecule | — | — |